Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease

Rheum-Pulm ILD Preceptorship: Case Based Insights With Academic Experts Bootcamp

Emerging Therapies in ILD

In this presentation, Corinne Young reviews the latest advances in therapies for interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), highlighting the promising results of nerandomilast, a phosphodiesterase-4B inhibitor with both antifibrotic and immunomodulatory effects. Phase 3 trials (FIBRONEER-IPF and FIBRONEER-ILD) demonstrated that twice-daily nerandomilast slowed lung function decline and improved outcomes across patient populations, including those with autoimmune-related disease. The discussion also covers the drug’s safety profile—showing fewer gastrointestinal side effects compared to existing antifibrotic agents—and emerging treatments such as inhaled treprostinil, which is being studied for pulmonary fibrosis beyond pulmonary hypertension. With multiple new agents and combination therapies on the horizon, these developments represent meaningful progress in the treatment and management of fibrotic lung disease.

Sjogren’s Disease and ILD

In this concise and clinically insightful discussion, Amanda Mixon, PA-C, breaks down what to look for when suspecting Sjögren’s syndrome—an autoimmune condition marked by chronic dry eye and dry mouth, fatigue, and systemic manifestations. Often associated with SSA and SSB antibodies, Sjögren’s can overlap with interstitial lung disease (ILD), making it especially important for pulmonary and rheumatology providers to recognize early. Learn how to distinguish classic symptoms from environmental causes, when to consider antibody testing, and which patients may be at higher risk for more severe complications like ILD. What you’ll learn: – Clinical clues for identifying Sjögren’s in practice – Role of SSA and SSB antibodies in diagnosis – Recognizing extra-glandular manifestations: fatigue, arthritis, rashes – When to suspect ILD in Sjögren’s patients – Medication options and early steroid use considerations Whether you’re in primary care, pulmonology, or rheumatology, this video equips you to ask the right questions and understand the systemic risks behind what may appear to be “just dry mouth.”

Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease

This webcast presents a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient cases, Janine Shinn, PA-C and Jasmine McElhany, PA highlight key risk factors such as age, seropositivity, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, identification of high-risk patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of multidisciplinary collaboration, proactive monitoring, and early referral for advanced care is reinforced to help improve patient outcomes.

Scleroderma Treatment

In this focused discussion, Amanda Mixon, PA-C shares a practical approach to managing patients with systemic sclerosis (Scleroderma), with an emphasis on individualized care based on disease manifestation. From echocardiograms to pulmonary imaging, medication choices to vascular complications, this talk provides key insights into how APPs can tailor care to improve outcomes. Learn how to approach limited vs. diffuse Scleroderma, when to avoid glucocorticoids, and how to manage complications like digital ulcers and pulmonary involvement. Key takeaways include: – When to use echocardiograms, CT scans, and other diagnostics – Medication strategies: Mycophenolate, Selenomab, CCBs, ARBs, and more – Avoiding glucocorticoids in diffuse disease and managing risk of renal crisis – Treating symptomatically: digital ulcers, skin fibrosis, and blood flow support This is a must-watch for APPs in rheumatology, pulmonology, or primary care managing patients with Scleroderma.

Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease

This webcast presents a case-based discussion on identifying and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, Amanda Sell, PA-C and Kelsey Cramer, AGACNP-BC, DNP highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important clinical findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The discussion also underscores the importance of multidisciplinary collaboration, proactive monitoring, and early referral for advanced care, including transplant evaluation, to improve patient outcomes.

Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease

This webcast features a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through practical clinical scenarios, Iris Zink, MSN, ANP-BC, APRN and Heather Bachert, MSN, ANP-BC highlight key risk factors such as high serologic markers, age, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early detection using pulmonary function tests and high-resolution CT imaging, identification of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of multidisciplinary collaboration, early referral for transplant evaluation, and supportive interventions such as pulmonary rehabilitation is reinforced to help preserve lung function and improve patient outcomes.

The Rheum-Pulm Interface: Bridging Specialties in SARD-ILD

In this session, Corinne Young and Wendy Simmons highlight the importance of a multidisciplinary approach to managing interstitial lung disease (ILD) in patients with systemic autoimmune and rheumatologic disorders. Collaboration between rheumatology, pulmonology, and radiology teams is key to early recognition, diagnosis, and treatment planning—especially given the high risk of ILD-related morbidity and mortality in conditions like systemic sclerosis, rheumatoid arthritis, lupus, and Sjögren’s syndrome. The discussion reviews ACR screening guidelines, emphasizing the role of high-resolution CT imaging, pulmonary function testing, and oxygen desaturation monitoring. It also covers evidence-based first-line and escalation therapies, including mycophenolate, cyclophosphamide, and rituximab, while underscoring the need for frequent assessment, early intervention, and coordinated care to improve patient outcomes.

Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease

This webcast offers a case-based exploration of identifying and managing interstitial lung disease (ILD) in patients with rheumatic diseases, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, clinicians Lori Reed, NP and Audrey Gibson, PA-C highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important clinical findings like inspiratory crackles and exertional desaturation. The discussion emphasizes early detection using pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The session also underscores the importance of multidisciplinary collaboration, proactive monitoring, and comprehensive patient care to help slow disease progression and improve outcomes.

IPF & PPF: Natural History, Diagnosis, and Management

In this educational session, Corinne Young breaks down the underlying mechanisms, progression, and management of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). The discussion covers common genetic and environmental risk factors—including family history, smoking, and occupational exposures—and explains how chronic inflammation leads to fibrosis and loss of lung elasticity. Listeners gain a clear understanding of how progressive pulmonary fibrosis is identified through lung function tests (FVC, DLCO) and imaging changes over time. The presentation also addresses treatment strategies, highlighting when corticosteroids may be appropriate, why long-term steroid use is limited, and how newer antifibrotic and immunomodulatory therapies are improving outcomes for patients with fibrotic lung disease.